Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fluticasone propionate
Drug ID BADD_D00947
Description Fluticasone propionate is a synthetic glucocorticoid[F4355,F4358][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358][FDA Label]. Fluticasone propionate was first approved in 1990[L5962].
Indications and Usage Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxis[FDA Label]as well as inflammatory and pruritic dermatoses[F4355]. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis[L8309,F4358].
Marketing Status approved
ATC Code R03BA05; R01AD08; D07AC17
DrugBank ID DB00588
KEGG ID D01708
MeSH ID D000068298
PubChem ID 444036
TTD Drug ID D0LC6K
NDC Product Code 81522-002; 22552-0043; 51927-0013; 0113-0028; 41163-023; 0135-0582; 55910-607; 63868-656; 69842-765; 70000-0110; 72559-002; 46439-8729; 51552-1310; 11822-0901; 0113-0285; 37808-340; 41520-553; 0173-0601; 0173-0720; 50594-319; 53002-1294; 53002-7691; 59310-505; 59310-515; 0363-0652; 63629-8662; 63629-8663; 66993-078; 68788-7788; 0054-3270; 0713-0631; 80267-000; 81522-005; 16812-005; 64918-1600; 11673-262; 0173-0602; 0173-0718; 49035-063; 50090-0934; 53943-006; 55910-773; 60505-6205; 0363-0881; 63629-8658; 63629-8659; 64525-8000; 66993-079; 68196-208; 68788-8446; 68788-9678; 68998-600; 72189-004; 63654-380; 63981-001; 68196-210; 69842-757; 71143-375; 81522-073; 38779-2760; 53873-078; 55018-301; 11673-388; 46122-684; 49035-362; 50090-6053; 53002-1310; 53002-7693; 55301-506; 59310-114; 59310-311; 60505-0829; 63187-638; 63187-959; 63868-400; 64024-007; 68788-6926; 69306-016; 69842-900; 0536-1373; 49076-5501; 52482-001; 64918-1700; 11673-103; 11822-1177; 30142-258; 30142-301; 0113-7117; 36800-222; 0363-0024; 64525-6560; 69168-380; 70000-0613; 79903-071; 52221-106; 36800-572; 41163-100; 41250-634; 45802-222; 50090-2880; 50383-968; 59310-525; 62011-0269; 0363-1205; 63187-957; 68071-2582; 68071-4868; 68462-427; 0536-1183; 71205-443; 72288-119; 80425-0263; 53873-079; 63190-0520; 64918-1118; 37835-997; 0173-0719; 49348-182; 50090-0916; 50090-6058; 53002-2294; 60432-264; 63187-021; 63187-806; 0363-5012; 63629-8660; 63629-8661; 66993-080; 68016-723; 69842-770; 70518-1655; 0713-0632; 15308-0200; 58175-0361; 21130-089; 37808-205; 45802-221; 50090-6055; 50383-700; 56062-107; 59310-200; 60505-0955; 68391-133; 69256-061; 69842-228; 72288-333; 76162-656; 76420-106; 80159-201; 50909-5175; 63379-001; 11673-220; 21130-122; 36800-128; 41520-703; 46122-386; 51672-4095; 67296-1463; 53104-7531; 65089-0033; 0135-0576; 0168-0332; 0173-0600; 45802-441; 49035-200; 50090-0968; 51316-074; 60429-195
UNII O2GMZ0LF5W
Synonyms Fluticasone | Flonase | Flovent HFA | HFA, Flovent | Cutivate | Fluticasone Propionate | Propionate, Fluticasone | Flixonase | Flixotide | Flovent
Chemical Information
Molecular Formula C25H31F3O5S
CAS Registry Number 80474-14-2
SMILES CCC(=O)OC1(C(CC2C1(CC(C3(C2CC(C4=CC(=O)C=CC43C)F)F)O)C)C)C(=O)SCF
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eye disorder06.08.03.001--Not Available
Eye irritation06.04.05.0030.000627%Not Available
Eye pain06.08.03.0020.000903%
Eye swelling06.08.03.0030.000184%Not Available
Eyelid oedema23.04.01.003; 10.01.05.001; 06.04.04.004--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Facial pain08.01.08.012--
Faeces discoloured07.01.03.0020.000184%Not Available
Fear19.06.03.001--Not Available
Feeling abnormal08.01.09.014--Not Available
Feeling hot08.01.09.009--Not Available
Flank pain20.02.03.006; 15.03.04.003; 08.01.08.007--
Folliculitis23.11.04.003; 11.02.01.053--
Fontanelle bulging18.04.04.001; 17.02.05.0060.000184%Not Available
Fracture12.04.02.001; 15.08.02.001--
Gastrooesophageal reflux disease07.02.02.0030.000627%
Gastrointestinal pain07.01.05.005--
Glaucoma06.03.01.0020.000369%
Haemolysis01.06.04.002--
Headache17.14.01.0010.008128%
Hepatic cirrhosis09.01.04.001--Not Available
Hepatic function abnormal09.01.02.0010.000184%Not Available
Herpes simplex23.11.05.004; 11.05.02.001--Not Available
Hyperacusis04.02.02.001; 17.04.03.003--Not Available
Hyperadrenocorticism14.11.01.009; 05.01.01.003; 24.08.02.005--Not Available
Hyperaesthesia23.03.03.080; 17.02.06.004--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.0020.000369%
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkinesia17.01.02.008--Not Available
Hypernatraemia14.05.04.0010.000184%
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 12 Pages